1. Não houve relação entre a expressão de p16 e a presença do HPV, pois todos os casos estudados foram negativos para a presença do vírus.
2. A ausência de expressão do p16 teve relação com o gênero masculino e a morfologia queratinizante.
3. Não houve relação entre a presença de p16 e os fatores de risco estudados (álcool e cigarro).
4. O p16 teve baixa expressão em carcinoma de cabeça e pescoço, comparado ao grupo controle e epitélio adjacente, porém sem diferença estatística significante. 5. O padrão de expressão de p16 foi semelhante para os casos de carcinoma
REFERÊNCIAS BIBLIOGRÁFICAS
1. Sturgis EM. International head and neck cancer epidemiology consortium: Update no. 8. Head Neck (2012), doi: 10.1002/hed.23192.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
3. Radoï L, Paget-Bailly S, Cyr D, Papadopoulos A, Guida F, Schmaus A, Cénée S, Menvielle G, Carton M, Lapôtre-Ledoux B, Delafosse P, Stücker I, Luce D. Tobacco smoking, alcohol drinking and risk of oral cavity cancer by subsite: results of a French population-based case-control study, the ICARE study. Eur J Cancer Prev. 2012; 12: 20-34.
4. Katanoda K, Yako-Suketomo H. Cancer mortality attributable to tobacco by selected countries based on the WHO Global Report. Jpn J Clin Oncol. 2012 Sep;42(9):866.
5. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours, World Health Organization Classification of Tumours. IARC Press, Lyon, 2005.
6. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009 Feb 20;384(2):260-5.
7. Meisels A, Morin C, Casas-Cordero M, Rabreau M. Human papillomavirus (HPV) venereal infections and gynecologic cancer. Pathol Annu. 1983;18 Pt 2:277- 93.
8. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001 Aug 15;92(4):805-13.
9. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
___________________________________________________________________ * Referências organizadas conforme o estilo dos Requisitos Uniformes para Originais submetidos a Periódicos Biomédicos (Vancouver).
10. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002 May;2(5):342-50.
11. Lingen MW, Xiao W, Schmidt A, Jiang B, Pickard R, Kreinbrink P, Perez- Ordonez B, Jordan RC, Gillison ML. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol (2012), http://dx.doi.org/10.1016/j.oraloncology.2012.07.002
12. Szarka K, Tar I, Fehér E, Gáll T, Kis A, Tóth ED, Boda R, Márton I, Gergely L. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential. Oral Microbiol Immunol 2009;4:314-8.
13. Acay R, Rezende N, Fontes A, Aburad A, Nunes F, Sousa S. Human papillomavirus as a risk factor in oral carcinogenesis: a study using in
situ hybridization with signal amplification. Oral Microbiol Immunol. 2008 Aug;23(4):271-4.
14. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol. 1999 Dec;9(6):405-11.
15. McLaughlin-Drubin ME, Meyers J, Munger K. Cancer associated human papillomaviruses. Current Opinion in Virology 2012;2:459–466.
16. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009 Nov 15;15(22):6758-62.
17. de Spíndula-Filho JV, da Cruz AD, Oton-Leite AF, Batista AC, Leles CR, de Cássia Gonçalves Alencar R, Saddi VA, Mendonça EF. Oral squamous cell carcinoma versus oral verrucous carcinoma: an approach to cellular proliferation and negative relation to human papillomavirus (HPV). Tumour Biol 2011;32:409-16.
18. Fujita S, Senba M, Kumatori A, Hayashi T, Ikeda T, Toriyama K. Human papillomavirus infection in oral verrucous carcinoma: genotyping analysis and inverse correlation with p53 expression. Pathobiology. 2008;75(4):257-64.
19. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012;36(7):945–54.
20. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, Woolgar JA, Helliwell TR, Triantafyllou A, Robinson M, Sloan P, Harvey-Woodworth C, Sisson D, Shaw RJ. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011 Oct 1;17(19):6262-71.
21. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006.
22. Fuessel Haws AL, He Q, Rady PL, Zhang L, Grady J, Hughes TK, Stisser K, Konig R, Tyring SK. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004;122:87- 93.
23. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV- related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012 Apr;34(4):459-61.
24. Thomas J, Primeaux T. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol. 2012 Apr;16(2):91-9.
25. Liang C, Marsit CJ, McClean MD, Nelson HH, Christensen BC, Haddad RI, Clark JR, Wein RO, Grillone GA, Houseman EA, Halec G, Waterboer T, Pawlita M, Krane JF, Kelsey KT. Biomarkers of HPV in Head and Neck Squamous Cell Carcinoma. Cancer Res. 2012 Oct 1;72(19):5004-5013.
26. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012 Jul;6 Suppl 1:S75-82.
27. Pérez-Sayáns M, Suárez-Peñaranda JM, Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM, García-García A. p16INK4a/CDKN2 expression and its relationship with oral squamous cell carcinoma is our current knowledge enough? Cancer Letters 2011, 306:134-141.
28. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S, Webster KR. Identification of CDK4 sequences involved in cyclin D1 and p16
29. Eshkoor SA, Ismail P, Rahman SA, Mirinargesi M, Oshkour SA. Increased protein expression of p16 and cyclin D1 in squamous cell carcinoma tissues. Biosci Trends. 2009 Jun;3(3):105-9.
30. Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006 Feb;85(2):74. 31. Ministério da Saúde (Brasil), Instituto Nacional do Câncer. TNM: Classificação de Tumores Malignos. 6. Ed. Rio de Janeiro: INCA, 2004.
32. Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol (2012), doi: 10.1093/ije/dys146.
33. Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009 Sep;15(6):388-99.
34. Tribius S, Hoffmann AS, Bastrop S, Görögh T, Haag J, Röcken C, Clauditz T, Grob T, Wilczak W, Tennstedt P, Borcherding A, Petersen C, Hoffmann M. HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncol. 2012 Nov;48(11):1178-84.
35. van Monsjou HS, Balm AJ, van den Brekel MM, Wreesmann VB. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol. 2010 Nov;46(11):780-5.
36. Rapidis AD, Gullane P, Langdon JD, Lefebvre JL, Scully C, Shah JP. Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. Oral Oncol. 2009 Apr-May;45(4-5):299-300.
37. Syrjänen KJ, Syrjänen SM, Lamberg MA, Pyrhönen S. Human papillomavirus (HPV) involvement in squamous cell lesions of the oral cavity. Proc Finn Dent Soc. 1983;79(1):1-8.
38. Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, Schwartz SM, Purdue MP, Pilarska A, Eluf-Neto J, Menezes A, McClean MD, Matos E, Koifman S, Kelsey KT, Herrero R, Hayes RB, Franceschi S, Wünsch-Filho V, Fernández L, Daudt AW, Curado MP, Chen C, Castellsagué X, Ferro G, Brennan P, Boffetta P, Hashibe M. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010 Feb;39(1):166-81.
39. Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012 Jul;6 Suppl 1:S104-20.
40. Rades D, Seibold ND, Gebhard MP, Noack F, Schild SE, Thorns C. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol. 2011 Oct;187(10):626-32.
41. Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, Wunsch- Filho V, Curado MP, Shangina O, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Daudt A, Menezes A, Bencko V, Mates D, Fernandez L, Fabianova E, Gheit T, Tommasino M, Boffetta P, Brennan P, Waterboer T. Low human papillomavirus prevalence in head and neck cancer: results from two large case–control studies in high-incidence regions. Int J Epidemiol 2011;40:489-502
42. Israels ED, Israels LG. The cell cycle. Oncologist. 2000;5(6):510-3.
43. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704-7. 44. Gandarillas A. The mysterious human epidermal cell cycle, or an oncogene- induced differentiation checkpoint. Cell Cycle. 2012 Oct 31;11(24).
45. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y, Wong DT. Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med. 2002;13(1):51-61. 46. Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008 Jul;30(7):946-63.
47. Romana PG. Cell alterations and molecular mechanisms in oral carcinogenesis. Int J Oral Maxillofac Surg (2010), doi:10.1016/j.ijom.2010.06.023. 48. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001 Mar 10;264(1):42-55.
49. Bressac-de Paillerets B. Discovery of a new gene frequently inactivated in human cancers: protein p16, a cell cycle regulator. Bull Cancer. 1994 Oct;81(10):853-6.
50. Ohta S, Uemura H, Matsui Y, Ishiguro H, Fujinami K, Kondo K, Miyamoto H, Yazawa T, Danenberg K, Danenberg PV, Tohnai I, Kubota Y. Alterations of p16 and
51. Mortier L, Marchetti P, Delaporte E, Martin de Lassalle E, Thomas P, Piette F, Formstecher P, Polakowska R, Danzé PM. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumor suppressor. Cancer Lett. 2002 Feb 25;176(2):205- 14.
52. Perez-Ordoñez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006 May;59(5):445-53.
53. Soni S, Kaur J, Kumar A, Chakravarti N, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology. 2005;68(4-6):314-25.
54. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geradts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol. 1998 Apr;152(4):865-9.
55. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol. 2001 Sep;37(6):498-504.
56. Shintani S, Mihara M, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, Wong DT. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol. 2002 Apr;38(3):235-43.
57. Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol. 2002 Jan;55(1):58-60.
58. Montebugnoli L, Cervellati F, Cocchi R, Farnedi A, Pennesi MG, Flamminio F, Foschini MP. Immunohistochemical expression of p16(INK4A) protein as a helpful marker of a subset of potentially malignant oral epithelial lesions: study on a series with long-term follow-up. Histopathology 2010;57:528-34.
59. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA. Molecular genetics of premalignant oral lesions. Oral Dis. 2007 Mar;13(2):126-33.
60. Erickson BK, Alvarez RD, Huh WK. Human papillomavius: what every provider should know. Am J Obstet Gynecol (2012), doi: 10.1016/j.ajog.2012.09.007.
61. Seaman WT, Andrews E, Couch M, Kojic EM, Cu-Uvin S, Palefsky J, Deal AM, Webster-Cyriaque J. Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J. 2010 Aug 19;7:194.
62. Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, Gill S, Frustino J, Wilding G, Loree T, Popat S, Sullivan M. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985- 2010. Oral Oncol. 2011 Nov;47(11):1048-54.
63. Bahnassy AA, Zekri AR, Saleh M, Lotayef M, Moneir M, Shawki O. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol. 2007 May 24;7:4.
64. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol. 2005 Mar;32 Suppl 1:S59-66.
65. zur Hausen H. Human papilloma viruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977;78:1-30.
66. Braakhuis BJ, Leemans CR, Brakenhoff RH. A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med. 2004 Jul;33(6):317-22.
67. Hennessey PT, Westra WH, Califano JA. Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J Dent Res. 2009 Apr;88(4):300-6.
68. Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, Challacombe S, Ficarra G, Flaitz C, Zhou HM, Maeda H, Miller C, Jontell M. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011 Apr;17 Suppl 1:58-72.
69. Braakhuis BJ, Brakenhoff RH, Meijer CJ, Snijders PJ, Leemans CR. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur J Cancer 2009;45:2935-9.
70. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008 Mar 19;100(6):407-20.
72. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 2010 Jul;46(7):492-6.
73. Zushi Y, Narisawa-Saito M, Noguchi K, Yoshimatsu Y, Yugawa T, Egawa N, Fujita M, Urade M, Kiyono T. An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. Am J Cancer Res. 2011;1:869-81.
74. Thavaraj S, Stokes A, Guerra E, Bible J, Halligan E, Long A, Okpokam A, Sloan P, Odell E, Robinson M. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol. 2011 Apr;64(4):308-12.
75. Ishibashi M, Kishino M, Sato S, Morii E, Ogawa Y, Aozasa K, Kogo M, Toyosawa S. The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control. Int J Clin Oncol 2011;16:646-53.
76. Nemes JA, Deli L, Nemes Z, Márton IJ. Expression of p16(INK4A), p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Sep;102(3):344-52.
77. Bagan JV, Jimenez Y, Murillo J, Gavaldá C, Poveda R, Scully C, Alberola TM, Torres-Puente M, Pérez-Alonso M. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg. 2007 Jan;65(1):46-9.
78. Popović B, Jekić B, Novaković I, Luković L, Konstantinović V, Babić M, Milasin J. Cancer genes alterations and HPV infection in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2010 Sep;39(9):909-15.
79. Won HS, Jung CK, Chun SH, Kang JH, Kim YS, Sun DI, Kim MS. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012 Oct;48(10):985-90.
80. Park K, Cho KJ, Lee M, Yoon DH, Kim J, Kim SY, Nam SY, Choi SH, Roh JL, Han MW, Lee SW, Song SY, Back JH, Kim SB. p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. Acta Otolaryngol (2012), doi:10.3109/00016489.2012.741327.
81. Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck. 2011 Nov;33(11):1622-7. 82. Pannone G, Rodolico V, Santoro A, Lo Muzio L, Franco R, Botti G, Aquino G, Pedicillo MC, Cagiano S, Campisi G, Rubini C, Papagerakis S, De Rosa G, Tornesello ML, Buonaguro FM, Staibano S, Bufo P. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer. 2012 Feb 29;7:4.
83. Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S. Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med 2009;38:104-8.
84. Coutlée F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol. 2002 Mar;40(3):902-7.
85. Winder DM, Ball SL, Vaughan K, Hanna N, Woo YL, Fränzer JT, Sterling JC, Stanley MA, Sudhoff H, Goon PK. Sensitive HPV detection in oropharyngeal cancers. BMC Cancer 2009, 9:440.
86. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, Stefani M, Dessy E. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 2008;28:2535-9.
87. Prasad ML, Patel SG, Shah JP, Hoshaw-Woodard S, Busam KJ. Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck. Head Neck Pathol. 2012 Jun;6(2):184-90.
88. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer. 2010 Feb 11;5:4.
89. Hong A, Jones D, Chatfield M, Soon Lee C, Zhang M, Clark J, Elliott M, Harnett G, Milross C, Rose B. HPV status of oropharyngeal cancer by combination HPV DNA/p16 testing: biological relevance of discordant results. Ann Surg Oncol (2012), doi:10.1254/s10434-012-2778-4.
Carey TE, Bradford CR. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck. 2010 May;32(5):562-7.
91. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol. 2009 Sep;3(3):186-94. 92. Hoffmann M, Tribius S, Quabius ES, Henry H, Pfannenschmidt S, Burkhardt C, Görögh T, Halec G, Hoffmann AS, Kahn T, Röcken C, Haag J, Waterboer T, Schmitt M. HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer - how valid is p16INK4A as surrogate marker? Cancer Lett. 2012 Oct 1;323(1):88-96.
93. Kim SH, Koo BS, Kang S, Park K, Kim H, Lee KR, Lee MJ, Kim JM, Choi EC, Cho NH. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer. 2007 Apr 1;120(7):1418- 25.
94. Stokes A, Guerra E, Bible J, Halligan E, Orchard G, Odell E, Thavaraj S. Human papillomavirus detection in dysplastic and malignant oral verrucous lesions. J Clin Pathol. 2012 Mar;65(3):283-6.
95. Simonato LE, Garcia JF, Sundefeld ML, Mattar NJ, Veronese LA, Miyahara GI. Detection of HPV in mouth floor squamous cell carcinoma and its correlation with clinicopathologic variables, risk factors and survival. J Oral Pathol Med. 2008 Nov;37(10):593-8.
96. de Oliveira MG, Ramalho LM, Gaião L, Pozza DH, de Mello RA. Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. Mol Med Report. 2012 Jul;6(1):163-6.
97. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, Li M, Dunne A, Kawachi N, Smith RV, Burk RD, Prystowsky MB. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol. 2011 Oct;24(10):1295-305.
98. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007 Dec 1;121(11):2465-72.
99. Luginbuhl A, Sanders M, Spiro JD. Prevalence, morphology, and prognosis of human papillomavirus in tonsillar cancer. Ann Otol Rhinol Laryngol. 2009 Oct;118(10):742-9.
100. Winder DM, Ball SL, Vaughan K, Hanna N, Woo YL, Fränzer JT, Sterling JC, Stanley MA, Sudhoff H, Goon PK. Sensitive HPV detection in oropharyngeal cancers. BMC Cancer. 2009 Dec 15;9:440.
101. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer. 2000 May 20;89(3):300-4.
102. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr;2(4):755-62.
103. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2011 Jul;13(4):377-81. 104. Bishop JA, Ma XJ, Wang H, Luo Y, Illei PB, Begum S, Taube JM, Koch WM, Westra WH. Detection of Transcriptionally Active High-risk HPV in Patients With Head and Neck Squamous Cell Carcinoma as Visualized by a Novel E6/E7 mRNA In Situ Hybridization Method. Am J Surg Pathol. 2012 Dec;36(12):1874-82.
APÊNDICE 1 - DADOS DOS PACIENTES AVALIADOS
Tabela 12. Dados dos pacientes - Grupo Controle Paciente Gênero Fumante Etilista Localização
Avaliação p16 PCR
HPV
Quantificação DNA Presença Intensidade Distribuição Células
1 Fem N.A. + Palato + 3 Esparsa B, Sb 0,1075
2 Masc N.A. N.A. Gengiva 0,0075
3 Fem N.A. N.A. Gengiva 0,2275
4 Fem Gengiva 0,3625
5 Fem N.A. N.A. Assoalho + 2 Esparsa B 0,5125
6 Masc N.A. N.A. Mucosa + 2 Esparsa B 0,1275
7 Fem N.A. N.A. Gengiva 0,095
8 Fem N.A. N.A. Gengiva 0,1375
9 Masc N.A. N.A. Mucosa 0,215
10 Fem + Gengiva 0,1075
N.A.: dado não avaliado (ausência de informações no prontuário) Intensidade: 1 (até 10%), 2 (10-30%), 3 (30-70%), 4 (mais de 70%) Células: B (Basal), Sb (Supra-basal), Sf (Superficial)
Tabela 13. Dados dos pacientes – Carcinoma Espinocelular de Boca Paciente Gênero
Idade
Diagnóstico Fumante Etilista Localização* T N M
Estágio do Tumor PCR HPV Quantificação DNA
1 Fem 67 + + Gengiva 3 2 X IVA 0,195
2 Masc 68 + + Língua 4 3 X IVB 0,1775
3 Masc 50 + + Língua 3 X X III 0,25
4 Masc 48 N.A. + Língua 4 2b 0 IVA 0,1975
5 Fem 56 + Gengiva 3 2 0 IVA 0,005
6 Fem 54 N.A. N.A. Língua 1 1 1 IVC 0,435
7 Masc 45 + + Assoalho 2 3 X IVB 0,37
8 Masc 56 N.A. N.A. Assoalho 4 2b 0 IVA 0,47
9 Fem 72 + Língua X X X N.A. 1,1025
10 Masc 45 + + Assoalho 4 2b 0 IVA 0,17
11 Masc 45 + + Língua 2 3 X IVB 0,18
12 Fem 25 Assoalho 3 2b 1 IVA 0,325
13 Fem 76 N.A. N.A. Língua X X X N.A. 0,6125
14 Masc 79 + Gengiva X X X N.A. 0,7175
15 Fem 67 + + Língua 1 0 X I 0,2375
16 Masc 34 + + Gengiva 2 X X II 0,0325
17 Masc 56 N.A. N.A. Língua 3 2 X IVA 0,19
18 Masc 46 + + Gengiva 4 3 X IVB 0,22
19 Masc 41 N.A. N.A. Gengiva 3 X X III 0,1795
20 Masc 41 + + Assoalho 3 2 0 IVA 0,0375
N.A.: dado não avaliado (ausência de informações no prontuário) *Casos 2 e 3 também apresentaram lesão em asssoalho.
Continuação - Tabela 13. Dados dos pacientes – Carcinoma Espinocelular de Boca Paciente Característica Queratinizante Característica